BioXcel Therapeutics
BTAI
49 hedge funds and large institutions have $3.22M invested in BioXcel Therapeutics in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 9 closing their positions.
71% more capital invested
Capital invested by funds: $1.89M → $3.22M (+$1.33M)
0.61% more ownership
Funds ownership: 0.48% → 1.09% (+0.61%)
0% more funds holding
Funds holding: 49 → 49 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
18% less call options, than puts
Call options by funds: $23K | Put options by funds: $28K
41% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.25M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$660K |
| 3 |
Squarepoint
New York
|
+$25.2K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$17.3K |
| 5 |
HF
HRT Financial
New York
|
+$13.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$27.1K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$22K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$16K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$16K |
| 5 |
Jane Street
New York
|
-$13.6K |
BTAI Hedge Fund Activity: Q4 2024 in Review
49 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q4 2024, worth a combined $3.22M — up 71% from $1.89M a quarter earlier.
Fund positioning in BTAI was balanced in Q4 2024: 9 funds opened new positions, 9 closed out, 10 added to existing stakes and 17 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.25M. The largest seller was Renaissance Technologies, cutting an estimated $27.1K.
- 49 institutional investors held BioXcel Therapeutics (BTAI) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $3.22M of BioXcel Therapeutics stock for Q4 2024, up 71% quarter-over-quarter.
- 9 funds opened new BioXcel Therapeutics positions in Q4 2024 and 9 closed out, a net change of 0 holders.
- The largest BioXcel Therapeutics buyer in Q4 2024 was Armistice Capital, an estimated $2.25M added.
- The largest BioXcel Therapeutics seller in Q4 2024 was Renaissance Technologies, an estimated $27.1K sold.
Based on aggregated 13F filings for Q4 2024.